Therefore, GWAS of large sample sizes may yet uncover genetic factors associated with response to anti-TNF therapy in RA, and larger cohorts enable separate analyses of the different types of anti-TNF drugs. The gene discussed is TNF; the disease is rheumatoid arthritis.